Ablynx Licenses Nanobodies to Wyeth for Clinically Validated Target
Successful development and commercialization could mean $212.5M for Wyeth.!--h2>
Ablynx and Wyeth Pharmaceuticals will team up to discover, develop, and commercialize Nanobodies® directed at the tumor necrosis factor alpha protein and its receptors that target diseases in multiple therapeutic areas, under an exclusive research collaboration and license agreement with.
Ablynx has granted Wyeth exclusive, worldwide rights to Nanobodies targeting the clinically validated target tumor necrosis factor alpha. The companies will together advance these biologics through preclinical development.
Potential payments to Ablynx could total up to $212.5 million for the successful development and commercialization of multiple products. This includes initial payment, research support, and milestone payments. In addition Ablynx will receive royalties on product sales.